<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701948</url>
  </required_header>
  <id_info>
    <org_study_id>4108</org_study_id>
    <nct_id>NCT00701948</nct_id>
  </id_info>
  <brief_title>New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn</brief_title>
  <acronym>NOSODIAG</acronym>
  <official_title>Interest of New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate new dosage of inflammatory markers or new inflammatory markers
      for the diagnosis of nosocomial bacterial infection. We made the hypothesis that these new
      dosages or new inflammatory markers could be more useful than dosage of inflammatory markers
      already used in clinical practice (especially the use of a combination of interleukins (6 or
      8) and C-reactive protein for the management of newborns with a clinical suspicion of
      nosocomial bacterial infection and especially could allow to avoid excessive treatment with
      antibiotics
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection.</measure>
    <time_frame>48 hours and at 72 hours</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Nosocomial Infection</condition>
  <arm_group>
    <arm_group_label>A-1</arm_group_label>
    <description>Proven nosocomial bacterial infection (NBI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-2</arm_group_label>
    <description>Possible NBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1</arm_group_label>
    <description>Absence of NBI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-2</arm_group_label>
    <description>Probable absence of NBI</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newborn hospitalized in neonatal intensive care unit with a clinical suspicion of
        nosocomial bacterial infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns &gt; 72 hours of life hospitalized in neonatal intensive or intermediate care
             unit presenting a clinical suspicion of NBI

        Exclusion Criteria:

          -  Early post-operative period ( surgery of less than 48 hours)

          -  Multiple malformations

          -  Newborn already included in the study for a previous septic events

          -  Newborn treated with antibiotics in the last 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Kuhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Kuhn, MD</last_name>
    <phone>33 3 88 12 77 86</phone>
    <email>Pierre.kuhn@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Pédiatrie 2 - Hôpital d'Enfants CHU de Dijon; 10 - bld Maréchal de Lattre de Tassigny</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Labenne, MD</last_name>
      <phone>33 3 80 29 33 57</phone>
      <email>marc.labenne@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Labenne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Bernard Gouyon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril Ferdinus, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard Lizard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie 2 - Hôpital de Hautepierre; 1 - Avenue Molière</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Kuhn, MD</last_name>
      <phone>33 3 88 12 77 86</phone>
      <email>Pierre.kuhn@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Kuhn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Astruc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît Escande</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Lavaux, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Emmanuel LAVOUE, directeur Adjoint</name_title>
    <organization>Organization: University Hospital, Strasbourg, France</organization>
  </responsible_party>
  <keyword>Late onset neonatal sepsis</keyword>
  <keyword>Nosocomial bacterial infection</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>multiplex dosage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

